What's Happening?
Arcutis Biotherapeutics, Inc. announced that its product ZORYVE has been awarded the 2025 Best of Beauty Breakthrough Award by Allure magazine. ZORYVE is the first FDA-approved medication for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis to receive this recognition. The award highlights ZORYVE's innovation in skincare, being the top prescribed branded topical therapy for these conditions. ZORYVE is available as a once-daily, steroid-free topical treatment in cream and foam forms, suitable for diverse skin and hair types. The product has been chosen by healthcare providers over a million times, emphasizing its safety and effectiveness.
Why It's Important?
The recognition of ZORYVE by Allure magazine as a breakthrough product underscores its impact on the dermatology field. This award not only enhances the product's visibility but also validates Arcutis Biotherapeutics' commitment to innovation in treating inflammatory skin conditions. The award could potentially boost ZORYVE's market presence and influence prescribing practices among dermatologists. For patients, this means access to a well-tolerated and effective treatment option that addresses multiple skin conditions without the use of steroids, which can have adverse effects with long-term use.
